PDC*line Pharma Company
PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells.
.jpeg)
Technology:
Cell therapy, Dendritic Cells
Industry:
Private, Tumor-Specific Antigens, Whole-Cell Antigens
Headquarters:
La Tronche, Rhone-Alpes, France
Founded Date:
2014-04-01
Employees Number:
1-10
Funding Status:
Early Stage Venture
Investors Number:
10
Total Funding:
41500000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2021-12-06
Last Funding Type:
Series B
Register and Claim Ownership